Get the Stockscreener App
6.75
3.02%
-0.21
After Hours:
6.71
-0.04
-0.59%
Valneva Se Adr stock is traded at $6.75, with a volume of 21,945.
It is down -3.02% in the last 24 hours and up +41.21% over the past month.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
See More
Previous Close:
$6.96
Open:
$6.68
24h Volume:
21,945
Relative Volume:
0.29
Market Cap:
$640.06M
Revenue:
$180.81M
Net Income/Loss:
$-160.71M
P/E Ratio:
-3.604
EPS:
-1.8729
Net Cash Flow:
$-88.46M
1W Performance:
-4.39%
1M Performance:
+41.21%
6M Performance:
-43.70%
1Y Performance:
-42.01%
1-Day Range:
$6.60
$6.7999
1-Week Range:
$6.60
$7.1021
52-Week Range:
$4.75
$12.23
Valneva Se Adr Stock (VALN) Company Profile
Compare VALN vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VALN
Valneva Se Adr
|
6.75 | 646.70M | 180.81M | -160.71M | -88.46M | -1.8729 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Valneva Se Adr Stock (VALN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-26 | Downgrade | Goldman | Neutral → Sell |
| Aug-19-25 | Resumed | H.C. Wainwright | Buy |
| Aug-03-22 | Initiated | H.C. Wainwright | Buy |
Valneva Se Adr Stock (VALN) Latest News
Research Analysts Issue Forecasts for Valneva Q3 Earnings - MarketBeat
Why Eton Pharmaceuticals Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket - Sahm
European Regulator Validates Pfizer and Valneva's Lyme Disease Vaccine Application - Sahm
Valneva Shares Surge as Europe Begins Review of First Lyme Disease Vaccine - finance.biggo.com
Valneva (NASDAQ:VALN) Sees Strong Trading VolumeWhat's Next? - MarketBeat
Pfizer, Valneva Lyme vaccine enters EMA review - grafa.com
Valneva SE earnings missed by $0.18, revenue fell short of estimates - Investing.com
Dow Falls Over 100 Points; US Consumer Sentiment Declines In August - Sahm
Valneva Q2 Earnings Call Highlights - Yahoo Finance
Valneva H1 2026 slides: loss widens as Lyme hopes build - Investing.com
Earnings call transcript: Valneva H1 2026 loss widens as Lyme hopes build - Investing.com Nigeria
Valneva (NASDAQ:VALN) Shares Gap UpHere's Why - MarketBeat
Valneva stock initiated at Buy by TD Cowen on Lyme vaccine potential - Investing.com
Valneva SE Sponsored ADR (NASDAQ:VALN) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Valneva SE (VALN) Investigation: Bronstein, Gewirtz & Grossman, L - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating Valneva SE (VALN) And Encourages Investors to Connect - The National Law Review
Valneva's Trading Restriction Lifts at an Awkward Moment as Analysts Square Off Over Vaccine Prospec - ad-hoc-news.de
Bronstein, Gewirtz & Grossman, LLC Is Investigating Valneva SE (VALN) And Encourages Stockholders to Connect - The National Law Review
AYJ0 Forecast — Price Target — Prediction for 2027 - TradingView
Bronstein, Gewirtz & Grossman, LLC Is Investigating Valneva SE (VALN) And Encourages Shareholders to Connect - The National Law Review
A3CPD1 Forecast — Price Target — Prediction for 2027 - TradingView
Valneva SE Sponsored ADR Actuals & Estimates (NASDAQ:VALN) - TradingView
VALN Q1 2026 Earnings: Significant EPS Miss Highlights Development‑Stage Cash BurnEstimate Dispersion - newsline.com
VLA.PA Technical Analysis | Trend, Signals & Chart Patterns | VALNEVA SE (EPA:VLA) - ChartMill
VALNEVA:Declaration of shares and voting rights - GlobeNewswire Inc.
VALN Q1 2026 Earnings: Significant EPS Miss Drives Stock DeclinePreliminary Results - dars.gov.et
VALNValneva SE ADR Stock Price and Quote - Finviz
Valneva (VALN) Holds Steady Near Support as Traders Weigh Near-Term CatalystsMarket Cap Weight - The Legal Advocate
VLA.PA Stock Price, Quote & Chart | VALNEVA SE (EPA:VLA) - ChartMill
Valneva SE (VALN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Valneva SE earnings missed by $0.24, revenue fell short of estimates - Investing.com
Valneva Q1 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Valneva SE Q1 2026 reports revenue decline, stock dips - Investing.com Nigeria
Earnings call transcript: Valneva SE Q1 2026 reports revenue decline, stock dips By Investing.com - Investing.com South Africa
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SEVALN - PR Newswire
Valneva’s €84M Cash Injection Comes With a Bitter Pill for Shareholders - AD HOC NEWS
Valneva faces securities fraud probe after Lyme vaccine trial misses key goal, shares drop 37%. - Pluang
Law firm probes Valneva over vaccine trial resu... - Pluang
Valneva shares slide after US pullback on chikungunya vaccine filing - MSN
Valneva (NASDAQ:VALN) Sets New 12-Month Low After Analyst Downgrade - MarketBeat
Valneva SE Sponsored ADR (NASDAQ:VALN) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Goldman Sachs downgrades Valneva stock rating to sell on Lyme vaccine uncertainty - Investing.com
Valneva's Dual Challenge: Legal Scrutiny Meets Commercial Reality - AD HOC NEWS
Guggenheim cuts Valneva stock price target to $11 on Lyme vaccine - Investing.com
Valneva faces investigation after Lyme vaccine trial misses primary goal, shares drop 37%. - Pluang
Valneva Se Adr Stock (VALN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.00%
3.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):